FDA approves Barr's generic version of Kos' cholesterol drug

04/28/2005 | Bloomberg Businessweek

The FDA granted final approval for Barr Pharmaceuticals to market a generic version of Kos Pharmaceutical's cholesterol drug Niaspan. The approval follows a licensing agreement between the two companies to settle a patent dispute clearing the way for Barr to market its generic product while also paying royalties to Kos.

View Full Article in:

Bloomberg Businessweek

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Claims Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Vice President, Idaho Regional Director
Boise, ID